Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2006

01-09-2006

Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha

Authors: Hye-Sook Seo, David G. DeNardo, Yves Jacquot, Ioanna Laïos, Doris Salazar Vidal, Carmen Rojas Zambrana, Guy Leclercq, Powel H. Brown

Published in: Breast Cancer Research and Treatment | Issue 2/2006

Login to get access
Metadata
Title
Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha
Authors
Hye-Sook Seo
David G. DeNardo
Yves Jacquot
Ioanna Laïos
Doris Salazar Vidal
Carmen Rojas Zambrana
Guy Leclercq
Powel H. Brown
Publication date
01-09-2006
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2006
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9191-2

Other articles of this Issue 2/2006

Breast Cancer Research and Treatment 2/2006 Go to the issue

Epidemiology

Incidence and risk factors associated with bilateral breast cancer in area with early age diagnosis but low incidence of primary breast cancer: analysis of 10-year longitudinal cohort in Taiwan

Preclinical study

Hypoxia inducible factor-1α correlates with VEGF-C expression and lymphangiogenesis in breast cancer

Preclinical study

LHRH-conjugated Magnetic Iron Oxide Nanoparticles for Detection of Breast Cancer Metastases

Epidemiology

Chronological changes of clinical characteristics in 31,115 new breast cancer patients among Koreans during 1996–2004

Preclinical study

Prognostic impact of Skp2 and p27 in human breast cancer

Preclinical investigation

A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits